The Government Accountability Office released a scathing report on the Food and Drug Administration’s oversight of medical‑device recalls, finding the agency rarely forces manufacturers to withdraw unsafe products and is hampered by severe staffing shortages.
What the GAO Report Revealed
The probe, launched at the urging of Senators Dick Durbin and Richard Blumenthal, examined the FDA’s handling of the 2021 recall of Philips Respironics breathing machines fitted with industrial foam that can break down and release toxic particles into patients’ lungs.
Despite hundreds of complaints over many years, the FDA never ordered a recall; Philips eventually did so after fielding thousands more complaints, but it did not notify the agency in a timely manner.
Patients who continued using the CPAP, BiPAP and ventilator devices reported respiratory illnesses, kidney and liver problems, and cancer. Since April 2021, the FDA has logged more than 500 reports of deaths linked to the devices.
The GAO found that the FDA has the statutory authority to compel recalls but has exercised it only four times, the last in 1992. In the past five years, roughly 900 recalls per year have been initiated voluntarily by manufacturers.
With a portfolio that now covers more than 190,000 medical devices—up about 15,000 since 2016—the agency’s reduced workforce, trimmed during the Trump administration, struggles to verify that manufacturers meet recall timelines and to keep consumers informed.
Why It Matters
Patients depend on medical devices for daily health maintenance; delayed or incomplete recalls can expose them to life‑threatening hazards. Dr. Rita Redberg highlighted that the FDA’s recall notices are still sent by fax, reflecting a “primitive” data infrastructure.
Former FDA associate commissioner Dr. Peter Lurie warned that ongoing staff cuts could further erode the agency’s ability to process recall status reports, which track notifications, repairs and timelines.
Senator Blumenthal emphasized that “FDA needs additional resources and staff to adequately protect Americans from unsafe medical devices,” warning that future staffing reductions could increase risk.
Potential Next Steps
The Department of Health and Human Services has said it will evaluate the need for more FDA staff and possibly greater legislative authority to manage recalls more effectively.
Legislation introduced by Senators Durbin and Rep. Jan Schakowsky would require the FDA to issue recall alerts in an electronic format, facilitating faster communication among manufacturers, the agency, hospitals and physicians.
If enacted, such a law could modernize the notification process and reduce the lag that left some patients unaware of the Philips recall for months or years. Additionally, increased staffing could help the FDA monitor recall status reports more consistently.
Frequently Asked Questions
How often has the FDA used its authority to force a medical‑device recall?
According to the GAO, the FDA has exercised its recall‑forcing authority only four times, with the most recent occurrence in 1992.
How many deaths have been reported in connection with the recalled Philips breathing devices?
The FDA’s latest update records more than 500 death reports associated with the devices since 2021.
What legislative measures are being proposed to improve the recall process?
Senator Durbin and Representative Schakowsky have introduced a bill that would require the FDA to create an electronic format for recall alerts, enabling quicker sharing of critical information among stakeholders.
What changes would you like to see in how medical device recalls are handled?
